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Background: Mucosally transmissible and pathogenic CCR5 (R5)-tropic simian-human immunodeficiency virus
(SHIV) molecular clones are useful reagents to identity neutralization escape in HIV-1 vaccine experiments and to
study the envelope evolutionary process and mechanistic basis for coreceptor switch during the course of natural
infection.
Results: We observed progression to AIDS in rhesus macaques infected intrarectally with molecular clones of the
pathogenic R5 SHIVSF162P3N isolate. Expansion to CXCR4 usage was documented in one diseased macaque that
mounted a neutralizing antibody response and in another that failed to do so, with the latter displaying a rapid
progressor phenotype. V3 loop envelop glycoprotein gp120 sequence changes that are predictive of a CXCR4 (X4)-
using phenotype in HIV-1 subtype B primary isolates, specifically basic amino acid substations at positions 11 (S11R),
24 (G24R) and 25 (D25K) of the loop were detected in the two infected macaques. Functional assays showed that
envelopes with V3 S11R or D25K mutation were dual-tropic, infecting CD4+ target cells that expressed either the
CCR5 or CXCR4 coreceptor. And, consistent with findings of coreceptor switching in macaques infected with the
pathogenic isolate, CXCR4-using variant was first detected in the lymph node of the chronically infected rhesus
monkey several weeks prior to its presence in peripheral blood. Moreover, X4 emergence in this macaque
coincided with persistent peripheral CD4+ T cell loss and a decline in neutralizing antibody titer that are suggestive
of immune deterioration, with macrophages as the major virus-producing cells at the end-stage of disease.
Conclusions: The data showed that molecular clones derived from the R5 SHIVSF162P3N isolate are mucosally
transmissible and induced disease in a manner similar to that observed in HIV-1 infected individuals, providing a
relevant and useful animal infection model for in-depth analyses of host selection pressures and the env
evolutionary changes that influence disease outcome, coreceptor switching and vaccine escape.
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The human immunodeficiency virus (HIV) enters target
cells through binding of its envelope glycoprotein gp120 to
the human CD4 receptor and a coreceptor, either CXCR4
(X4 HIV) or CCR5 (R5 HIV) [1]. Over 80% of HIV-1 trans-
missions are initiated with R5 viruses [2-6], with X4 or
dual-tropic viruses that use both CCR5 and CXCR4 (R5X4)* Correspondence: cmayer@adarc.org
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reproduction in any medium, provided the oremerging and coexisting with R5 viruses in 40-50% of non-
treated subtype B and D infected individuals late in infec-
tion, but less often in subtype A and C infected patients
[2,7-11]. Emergence of CXCR4-using viruses is frequently
accompanied by rapid peripheral CD4+ T cell loss and pro-
gression to end-stage disease [12], but the mechanism(s)
underlying their expansion is not well understood. It has
been suggested that X4 viruses evolve from transmitted R5
viruses to broaden target cell populations [13], transitioning
via an intermediate stage with respect to the envelope se-
quence and phenotypic characteristics [14,15]. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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both phenotypically and genotypically [11,16-23], the latest
from analysis of transmission clusters [24], with suppres-
sion of their replication following the development of HIV-
specific immunity [16-18]. The finding that recently
emerged CXCR4-using variants in some HIV-1 infected
individuals are more neutralization sensitive than coexisting
R5 viruses further supports a role of immune-mediated se-
lection pressure against X4 virus [25]. Transmission and se-
lection against CXCR4-using SIVsm in vivo [26], as well as
emergence in the chronic phase of infection of variants that
were transmitted but were not maintained at detectable
levels early in infection have also been reported in SIV [27]
and SHIV [28] infected monkeys. Thus, the possibility
exists that R5-to-X4 conversion late in infection is the re-
sult of re-emergence of co-transmitted X4 or R5X4 variants
when the immune system collapses.
Experimental infection of Asian macaques with simian
(SIV) or simian-human immunodeficiency (SHIV) viruses
are recognized as playing a critical role in advancing our
understanding of HIV-1 transmission, pathogenesis, as
well as basic vaccine, prevention and treatment concepts
[29-31]. SHIVs that express the HIV-1 envelope glycopro-
teins (Envs) are particularly suited as challenge viruses to
evaluate the role of viral tropism in AIDS pathogenesis
and neutralizing antibody protection in the macaque
model. The early pathogenic SHIVs primarily expressed
CXCR4-using Envs and induced a disease course that dif-
fered from those observed in HIV-1 infected individuals
and SIV-infected rhesus [32-35]. Subsequently, several
clade B and C R5 SHIVs have been constructed that
showed varying degree of mucosal transmissibility, repli-
cation competence and pathogenicity [34,36-40], but R5
SHIV molecular clones that induce a HIV-1 like pathology
including coreceptor switch coincident with peripheral
CD4 decline and predominance of macrophage tropism at
end-stage disease have not been described. We developed
a model of experimental infection of Asian macaques with
the late-stage SHIVSF162P3N isolate that exhibited many
similarities to HIV-1 infection in humans including CCR5
coreceptor usage, mucosal transmissibility, acute depletion
of mucosal memory CD4+ T cells, persistent infection,
and progression to AIDS over a period of several months
to years in a proportion of the infected animals [41,42].
Moreover, expansion or switch to CXCR4 was observed in
~50% of R5 SHIVSF162P3N-infected AIDS macaques, with
viruses that can function with both coreceptors serving as
intermediates [43,44]. Similar to HIV-1, the main determi-
nants for coreceptor usage of SHIVSF162P3N are located in
the third (V3) variable loop of Env [43,44]. However,
whereas coreceptor switch in most HIV-1 infected indivi-
duals occurred following the development of antiviral
antibodies, the macaques in which coreceptor switch was
observed were primarily rapid progressors (RPs) that failedto mount or sustain an antiviral antibody response. Thus,
there is concern that the selective pressures for phenotypic
conversion in the RP macaques might not fully reflect the
human situation. Furthermore, because the populations in
the SHIVSF162P3N virus stock are comprised of related but
not identical variants, the presence of low-level X4 viruses
in the inoculum that were initially co-transmitted and
remaining cryptic until immune selective pressure is suffi-
ciently diminished cannot be excluded. For these reasons,
we generated molecular clones of R5 SHIVSF162P3N for
intrarectal inoculation, with the objective of documenting
disease development and a shift in coreceptor preference
during the course of natural infection. Mucosally trans-
missible, highly replication competent and pathogenic R5
SHIV molecular clones would also be very useful as chal-
lenge viruses in vaccine efficacy and escape studies.
Results
Envelope sequence and function of SHIVSF162P3N
molecular clones
The V3 loop of envelope gp120 plays a major role in core-
ceptor usage, tropism and neutralization susceptibility, fac-
tors that modulate viral pathogenesis [45]. Accordingly, two
major V3 loop species, each representing 14 of 43 envelope
clones sequenced in the R5 SHIVSF162P3N virus quasispecies
[41], were chosen for construction of SHIVSF162P3N molecu-
lar clones to assess their utility in studies of lentiviral patho-
genesis and AIDS vaccine. Comparison of the env gp160 of
the two molecular clones showed differences only in gp120.
The net positive charge for the V3 variable loop of clone 8
is +5 as compared to +4 for clone 11, with notable differ-
ences between the two clones in the V4 and V5 domains,
and in the potential N-linked glycosylation sites (PNGSs) as
well. Specifically, there was a repositioning of a PNGS in
the V1V2, with a loss of PNGS in the V4 domain of clone 8
gp120 as compared to clone 11 gp120 (Figure 1A). Both
Envs function only with CCR5, infecting U87.CD4 cells
expressing CCR5 but not CXCR4, with no significant differ-
ence in their entry efficiency into TZM-bl cells that express
high levels of CD4 and CCR5 (Figure 1B). However, clone 8
infected primary macrophages more efficiently, and was 2-
fold more sensitive to neutralization with sCD4 than clone
11 (90% inhibitory concentration IC90 1.7 μg/ml vs 3.0 μg/
ml; Figure 1C), suggesting that it binds to the CD4 receptor
with higher affinity.
R5 SHIVSF162P3N molecular clones are infectious by the
intrarectal route and induce disease
We next tested the mucosal transmissibility and patho-
genicity of SHIVSF162P3N clones 8 and 11. We confirmed
CCR5 usage of the two molecular clones in rhPBMCs by
demonstrating that the CCR5 inhibitor TAK779 and not
the CXCR4 inhibitor AMD3100 blocked replication of
these viruses (Figure 2A). Five of five macaques inoculated
AB C
Figure 1 Envelope sequence and function of R5 SHIVSF162P3N molecular clones. (A) Comparison of envelope gp160 sequence of
SHIVSF162P3N clones 8 and 11. Dots denote identical residues in the sequence and * indicates potential N-linked glycosylation sites (PNGSs). PNGSs
that are absent or re-positioned in clone 8 envelope gp120 are designated by black and red boxes, respectively. (B) Entry into TZM-bl cells and
U87.CD4 indicator cell lines, and (C) sCD4 sensitivity and infection of primary macrophages that express low levels of CD4 with pseudotyped
viruses bearing clone 8 and 11 Env gp160. Infectivity in macrophages was expressed as a ratio of infectivity in autologous PBMCs that express
high levels of CD4 and CCR5. RLU, relative light unit. All viral entry and infectivity experiments were tested in triplicates. Data shown are the
means and standard deviations from triplicate wells and are representative of at least two independent experiments.
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with peak viremia of 6–7 log10 RNA copies/ml plasma
(Figure 2B). Four of the five clone 11-infected macaques
controlled their infection to levels ≤ 3 log10 RNA copies/
ml plasma after 20 weeks of infection, with one, EN31,
sustaining high viral load (>7 log10 RNA copies/ml
plasma). EN31 developed clinical symptoms of AIDS, and
was euthanized at 23 weeks post-infection (wpi). In com-
parison, while virus replication also declined in the post-
acute phase in three of the five clone 8-infected macaques,
a rebound to levels of 4 log10 RNA copies/ml plasma was
seen in one of these three animals at 40 wpi. Moreover,
the remaining two clone 8-infected monkeys maintained a
steady state level of 5 log10 RNA copies/ml plasma, with de-
velopment of disease at 95 and 100 wpi (FF94 and FD83,
respectively). These results show that both R5 SHIVSF162P3N
molecular clones are mucosally transmissible and arepathogenic, but viremia appeared to be more persistent in
the clone 8- than the clone 11-infected macaques.
Severe lymph node CD4 T cell loss in macaques infected
with R5 SHIVSF162P3N molecular clones that developed
disease
Analysis of peripheral CD3 + CD4+ T cells in the three
macaques (EN31, FF94, FD83) that progressed to disease
showed transient loss in the clone 11-infected macaque
EN31 during peak viremia (2–3 wpi) that rebounded to
baseline levels at 6 wpi (Figure 3). By 12 wpi, however,
peripheral CD4+ T cell count began to decline, with pre-
cipitous drop to < 2 cells/μl blood at end-stage disease.
Peripheral CD4+ T cell loss was more gradual and pro-
tracted in the two clone 8-infected animals. At the time
of euthanasia, CD4+ T cell count in FF94 and FD83 was
5 and 61 cells/μl blood, respectively. Significant acute
Figure 2 SHIVSF162P3N clone 8 and 11 replication in intrarectally challenge macaques. (A) Coreceptor usage in rhPBMC and the V3 loop
sequence of SHIVSF162P3N clone 8 and 11, and (B) plasma viral RNA levels over time in the infected animals are shown. Coreceptor usage of the
inoculating viruses was determined by blocking entry into rhPBMC with 1 μM CXCR4-specific (AMD3100) or CCR5-specific (TAK779) inhibitor. For
V3 loop sequence, dashes stand for identity in sequences, and the net positive charge of this region is shown on the right. † in (B) indicates
euthanasia with clinical symptoms of AIDS.
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observed only in the lamina propria (LP) of the intestine
of FF94, with minimal loss in the peripheral lymph
nodes (LNs) of all three animals (Figure 3B). The more
dramatic acute depletion of gut CD4 cells in FF94 as
compared to EN31 and FD83 may be related to the factFigure 3 Severe CD4+ T cell loss in RMs infected with SHIVSF162P3N m
count in RMs that developed clinical symptoms of AIDS. Horizontal line de
T cells in the lamina propria lymphocyte (LPL) from the jejunum, iliac, colon
(2 wpi) and at time of necropsy. Baseline values generated from three uninthat surgery was performed one week later in FF94
(3 wpi) than in the other two. At the time of necropsy,
however, >99% of CD4+ T lymphocytes in the gut of all
three macaques were depleted. Massive depletion of
CD4+ T cells was also seen in the LNs of EN31 and
FF94 at the time of euthanasia, but 20-35% of this T cellolecular clones. (A) Plasma viral load and peripheral CD4+ T cell
notes CD4+ T cell count of 200 cells/ul blood. (B) Percentages of CD4+
ic (col) and mesenteric (Mes) lymph nodes during acute viremia
fected macaques are shown for reference.
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FD83. The severe loss in peripheral as well as lymphoid
CD4+ T lymphocytes in EN31 and FF94 at the time of eu-
thanasia is suggestive of X4 presence, prompting us to
analyze envelope sequences in the tissues of these animals.
Coreceptor switch in macaques infected with R5
SHIVSF162P3N molecular clones
Envelope sequence analysis revealed that, in contrast
with FD83, five of eight clones amplified from the lymph
node of EN31 at the time of necropsy harbored arginine
at position 11 of the V3 loop (S11R), while those in FF94
had, at position 25, either lysine (D25K; 23 of 24 clones)
or arginine (D25R; 1 of 24 clones) residue (Figure 4A).
Basic amino acid substitutions at these positions of the
V3 loop are strongly associated with a CXCR4-using
phenotype in HIV-1 infected individuals [46-49]. More-
over, substitution at position 25 of the V3 loop of FF94
was frequently accompanied by the introduction of an
arginine at position 24 that had been reported to im-
prove the predictive value of X4 presence in humans
[50]. Functional assays showed that in contrast with
Envs bearing WT V3 sequence that use only CCR5 for
entry, Envs harboring V3 S11R (EnvS11R) or D25K mu-
tation (EnvD25K) were dual-tropic, infecting U87.CD4
cells that expressed either the CCR5 or CXCR4 corecep-
tor (Figure 4B). Interestingly, deep sequencing of gp120
V3 in the clone 11 inoculum (21,048 reads) revealed
presence of the S11R mutation at very low frequency
(0.07%), raising the possibility of X4 evolution during
clone expansion in vitro. S11R substitutions as a result
of a single nucleotide point mutation were also detected
in the SHIVSF162P3N clone 8 virus stock (0.11%; 37,360
reads). But the D25K mutation associated with pheno-
typic switch in FF94 was absent, supporting evolution to
CXCR4-use in vivo.
Peripheral lymph nodes were found to be the preferred
sites of X4 emergence and expansion in macaques infected
with R5 SHIVs [42,51,52]. Because longitudinal samples
(w8, 46, 54, 84) from the inguinal lymph node (Ing LN) of
FF94 were available, we analyzed this tissue compartment
as well as the PBMC and serum samples collected at the
corresponding time points for X4 emergence in this ani-
mal. We found that the dual-tropic D25K V3 variant was
detected by clonal analysis at low frequency (1 of 21 clones
sequenced) in the Ing LN of FF94 sampled at 46 wpi. Rep-
resentation of this variant in the Ing LN increased over
time, with all 24 clones sequenced harboring this mutation
at 84 wpi (Figure 4C). The D25K variant was not detect-
able in the blood by clonal sequence at 46 and 50 wpi,
emerging in plasma and PBMCs sampled four weeks later.
Representation of the V3 variant increased over time in
blood cells, becoming the major Env species from 68 wpi
until the time necropsy. In contrast, the D25K variantco-existed with R5 viruses in the plasma at all time points
analyzed. Collectively, the results confirm and extend our
findings with the isolate [42], demonstrating mutational
pathways to CXCR4-usage that overlapped with those seen
in HIV-1 infected individuals, with X4 evolution and
emergence first in secondary lymph nodes.
Tropism switch following the development of a
neutralizing antibody response
Both EN31 and FF94 seroconverted at 3 wpi. SHIV-
binding antibody titers continued to increase in FF94,
reaching peak endpoint titers >6 log10 at 30–40 wpi, but
plateaued at 4–5 log lower levels in EN31 (Figure 5).
EN31 also failed to mount a neutralizing antibody (NAb)
response against the inoculating virus (clone 11), as has
been described for some HIV-1 infected individuals [53].
Homologous NAb against the clone 8 virus however was
detected in FF94 beginning at 12 wpi, and continued to
increase, reaching 50% inhibitory dilution (ID50) titers
>200 at 30–40 wpi. Titers declined thereafter, to ID50
levels <50 at the time of euthanasia. The high viral load,
weak antiviral antibody response and disease develop-
ment in EN31 within 30 weeks of infection classified this
animal as a rapid progressor, while FF94 displayed a more
typical disease course. These results with R5 SHIVSF162P3N
molecular clones show that similar to HIV-1 infected indi-
viduals, coreceptor switch in rhesus macaques occurs
in rapid progressors as well as in conventionally infected
animals that mounted a neutralizing antibody response.
Moreover, X4 emergence in FF94 coincides with persistent
peripheral CD4+ T cell-depletion below 200 cells/ul blood
(Figure 3) and a decline in neutralizing titers against the
inoculating virus (Figure 5) that are suggestive of immune
deterioration.
Tissue macrophages sustain virus production in FF94
The persistence of high viral load, with a rise towards
end-stage disease despite near complete depletion of
peripheral CD4+ T cells in FF94 prompted us to investi-
gate the source of virus production. Combined in situ
hybridization and immunohistochemistry staining with
SIVnef and Iba-1 showed that the majority of SHIV-
infected cells in the mesenteric LN of FF94 (>85%) are
lba-1 positive, indicating that they are of the macrophage
lineage (Figure 6). In comparison, only ~35% of SIVnef +
cells in EN31 are stained with the lba-1 antibody. Macro-
phages, therefore, are the principal virus-producing cells
in FF94 at end-stage disease.
Discussion
The origin of CXCR4-using variants has been investi-
gated extensively. This is because X4 presence is known
to be associated with poorer clinical prognosis, and is a
major concern in the clinical use of CCR5 inhibitors
Figure 4 V3 loop sequence (A), coreceptor usage (B) and distribution (C) of viruses in macaques infected with R5 SHIVSF162P3N
molecular clones. (A) V3 loop sequence comparison of the inoculating clonal virus and representative lymph node viruses in macaques EN31
(clone 11; colonic), FF94 (clone 8; mesenteric) and FD83 (clone 8; colonic) at time of necropsy. Dashes stand for identity in sequences, and the
net positive charge of this region is shown on the right. Positions 11 and 25 within the V3 loop are indicated by triangles, with brackets
highlighting the presence of positively charged amino acids at these positions. The numbers in parentheses represent the numbers of clones
matching the indicated sequence per total number of clones sequenced. (B) Infection of U87.CD4.CCR5 and U87.CD4.CXCR4 indicator cells with
pseudovirions bearing S11R, D25K or WT V3 sequences. RLU, relative light units. Data are the means and standard deviations from triplicate wells
and are representative of at least two independent experiments. (C) Distribution of viruses in Inguinal LN, PBMC and plasma of FF94 over time as
determined by clonal sequence analysis. Numbers in parentheses indicate number of gp120 clones sequenced at each time point.
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pothesis that X4 and R5X4 viruses evolved from pre-
existing R5 variants which are the founder viruses in
most cases of HIV-1 transmission. However, the bulk of
the evidence in support of early R5 dominance in
humans is made using blood from subjects who mani-
fested clinical signs of acute infection syndrome, several
weeks after the initial transmission event. Thus, the pos-
sibility that coreceptor switch during HIV-1 infection is
the result of re-emergence of co-transmitted X4 or
R5X4 viruses that reside in tissue sites that are not
sampled or exist at levels below the threshold of detec-
tion cannot be excluded. Using a relevant nonhuman
primate model of HIV-1 pathogenesis, we demonstratein this study that R5 SHIVSF162P3N molecular clones are
efficiently transmitted to macaques via intrarectal inocula-
tion, with disease induction and switch in coreceptor trop-
ism following the development of a neutralizing antibody
response. Furthermore, we obtain evidence suggestive of a
role of antibody selective pressure in counteracting X4
evolution and expansion.
Molecular clones of subtype B [59] and subtype C
[60,61] R5 SHIVs that are mucosally transmissible, highly
replication competent and capable of inducing AIDS in
rhesus macaques have been described, but expansion or
conversion to CXCR4 usage has not been observed. In this
regard, we show that both R5 SHIVSF162P3N molecular
clones exhibited coreceptor switching that followed the
Figure 5 SHIV-specific antibody response. SHIV binding and homologous neutralizing antibody titers in EN31 (clone 11) and FF94 (clone 8)
are shown. Closed arrows indicate time points when Ing LN biopsies were collected and analysed, with open arrow indicating time of
X4 detection.
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macaque EN31, serine at position 11 of the V3 loop was
substituted with arginine, while in FF94, the chronic pro-
gressor that mounted an autologous neutralizing antibody
response, the aspartic residue at position 25 was replaced
with either lysine or arginine residues (Figure 4A). In 17/
24 clones amplified from LN of FF94 at end-stage, this
substitution at position 25 was accompanied by introduc-
tion of a charged residue at position 24 of the V3 loop that
had been reported to improve the predictive value of X4
presence in humans [50]. Moreover, the D25K V3 muta-
tional event in FF94 occurred first in the lymph node
where naïve T cells that express high levels of CXCR4 are
enriched, in agreement with data published by us and
others that peripheral LNs are the prefer sites of X4 evolu-
tion and amplification [42,51,52]. Notably, emergence of
the dual-tropic D25K variant in the LN was in the pres-
ence of neutralizing antibody (ID50 titers of ~150 against
the inoculating clone 8 virus at 46 wpi; Figure 5), with
clonal analysis of the viral quasispecies showing increasing
dominance of the D25K V3 variant in LN and blood cells,
but not in the plasma (Figure 4C). These findings are con-
sistent with observations in HIV-1 infected individuals ofFigure 6 Tissue macrophages are the primary SHIV-infected cells at e
staining of the mesenteric LN of FF94 and EN31 for SIVnef (brown) and the
representative double-positive cells.a higher prevalence of X4 viruses in PBMCs compared to
serum [62-64], and support the notion that X4 viruses
emerge and predominate in body compartments with
lower antibody pressure than in the plasma, spreading via
cell-to-cell transmission that is less susceptible to antibody
neutralization. Recently emerged CXCR4-using variants in
some HIV-1 infected patients have been reported to be
more neutralization sensitive than coexisting R5 viruses
[25], implying that systemic dissemination is possible only
with immune system erosion that decreases the selection
pressure. X4 detection in peripheral blood of FF94 at 54
wpi coincides with persistent CD4+ T cell loss to levels
<200 cells/μl blood (Figure 3A) and a decline in neutraliz-
ing titers against the homologous inoculating virus that are
suggestive of immune erosion (Figure 5). It will be of inter-
est to investigate neutralization sensitivity of the emerging
and late CXCR4-using variants in FF94 to contemporary
sera to link a decline in autologous neutralization antibody
response with X4 emergence.
The infectious molecular clones were obtained by trans-
vated rhesus PBMC to generate virus stocks. This
expansion process in vitro necessarily introduces mutation
fection of 293 propagated in acti-but cultured andT cellsnd stage disease in FF94. Double-labeled immunohistochemical
macrophage marker lba-1 (red) was performed. Arrows mark
Ren et al. Retrovirology 2013, 10:9 Page 8 of 13
http://www.retrovirology.com/content/10/1/9and diversity, raising the possibility that the V3 mutations
identified with tropism switch in the infected animals
might have already been present in the inoculum. Deep
sequencing of V3 region in the SHIVSF162P3N clone 11
virus stock indicated that this is indeed the case. Fifteen of
over 21,000 sequences analyzed (0.07%) harbored the
S11R mutation, raising the possibility that the R5X4 vari-
ant could have been co-transmitted and eventually out-
grew in macaque EN31 which failed to mount a
neutralizing antibody response. In contrast, while the
S11R variant was also present in the SHIVSF162P3N clone 8
virus stock (0.11%), it was not detected by clonal sequence
analysis in the conventional macaque FF94 at terminal
disease stage. It is conceivable that the S11R variant was
not co-transmitted in this animal. Alternatively, it was co-
transmitted but remained cryptic. Further studies are
needed to examine these possibilities. But importantly,
deep sequencing failed to reveal the presence of D25K
mutation associated with tropism switch in FF94 in the
clone 8 virus inoculum, consistent with findings that mul-
tiple long-term cultures of clonal virus variants on PBMCs
results in only very few mutations in the V3-V4 regions
[65]. We conclude, therefore, that the V3 mutations that
confer CXCR4 usage in FF94 evolved from pre-existing
R5 variants. Analysis of recombinant V3 mutant viruses
showed that while the S11R mutation conferred efficient
CXCR4 usage, the D25K V3 mutant entered CXCR4-
expressing cells less efficiently than cells expressing CCR5,
in agreement with findings in infected individuals that
changes in V3 position 25 alone are not highly predictive
of coreceptor switching. Besides the V3 loop, mutations in
V1V2 domain of gp120 can also influence coreceptor
choice [66-73], consistent with structural studies in which
both V3 and the stem of the V1V2 loop were shown to
participate in coreceptor binding [74-76]. Furthermore,
in vitro studies suggested that the order of occurrence of
mutations associated with coreceptor switching is critical
for survival of the intermediates, with mutations in V1/V2
preceding those of V3 to permit virus survival [77].
Detailed analysis of env sequence changes over time in
FF94, in particular the V1/V2 domain of gp120, and the
relationship of these changes to autologous neutralizing
antibody response and viral fitness should provide import-
ant insights into the requirements and constraints for evo-
lution from CCR5 to CXCR4 use in vivo.
We previously reported sustained viremia and progres-
sion to disease over a one-year infection period in ten of
eleven rhesus macaques infected intrarectally with high
dose of the R5 SHIVSF162P3N isolate, with a RP phenotype
and coreceptor switching observed in four and five of
the eleven monkeys with AIDS respectively [78]. In this
regard, although the results with the molecular clones
confirm and extend findings with the isolate, showing
similar evolutionary pathways, dynamics and sites of X4emergence [42-44], infection with the molecular clones is
less pathogenic. The decrease in replicative capacity and
pathogenicity of R5 SHIVSF162P3N molecular clones may
be related to the fact that they are less diverse than the
isolate. Indeed, transmission of multiple viral variants has
been suggested to influence viral persistence and rates of
disease development through recombination to generate
intrahost phenotypic and pathogenic diversities to escape
early host selective pressures and increase fitness [79-82].
And, although the number of animals used is small, the
findings suggest that SHIVSF162P3N clone 8 may be more
pathogenic than clone 11. A higher proportion of the
clone 8-infected macaques sustained viremia (3 of 5) and
progressed to disease (2 of 5) over a two-year observation
period as compared to only one of five of the clone 11-
infected monkeys. The envelope glycoproteins of the two
clones differed in sCD4 sensitivity and as well as infection
of macrophages that are long-lived viral reservoirs [83].
Macrophages have been reported to be the principal reser-
voir and sustain high viral loads in rhesus monkeys
after the depletion of CD4+ T cells by highly pathogenic
X4 SHIVs [84], and following coreceptor switch in R5
SHIVSF162P3N-infected RPs [85]. Infected macrophages
are relatively resistant to CD8+ T cell-mediated suppres-
sion [86,87] and macrophage internal HIV-1 is protected
from neutralization antibodies [88]. Combined in situ
hybridization and immunohistochemical analysis of LNs
obtained at the time of necropsy indicated higher viral
burden in the LNs of FF94 than EN31, with a majority
(>80%) of infected cells in the former co-staining with lba-
1, a macrophage marker. Thus, it is tempting to speculate
that the difference in macrophage infection by the two
molecular clones contributed to their differences in viral
persistence. Studies in additional animals will be needed
to address this. Regardless, the data support the use of
both SHIVSF162P3N molecular clones to assess the efficacy
of vaccines in preventing HIV-1 acquisition or in reducing
peak viral load and virus-induced depletion of gut CD4+
T cells, but clone 8 may be more useful than clone 11 in
judging the effects of vaccines in dampening the intensity
of virus infection.
Conclusions
In summary, this report documents coreceptor switch in
macaques infected with R5 SHIV molecular clones, sup-
porting R5 evolution to X4. Coreceptor switch in maca-
ques infected with R5 SHIVSF162P3N molecular clones
required genetic adaptations similar to those seen in
humans, and occurred in rapid as well as conventional
progressors that mounted a neutralizing antibody re-
sponse. This animal model, in which the envelope se-
quence and functional properties of the inoculating virus
are known, and where detailed samplings of blood and tis-
sue samples are possible, provides the unique opportunity
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to uncover in detail the genetic requirement, obstacles
and constraints for virus phenotype evolution in vivo. It
can also be used to study neutralization escape during the
course of infection and determine the role of humoral im-
munity in X4 virus emergence. Lastly, because the mo-
lecular clones express R5 HIV-1 envelope glycoproteins,
main targets for neutralizing antibodies, they are better
suited than the X4 SHIVs and SIVs that differ antigenically
from HIV-1 as challenge viruses for antibody-based vac-
cine testing and development.
CXCR4, and containing integrated reporter genes for firefly
luciferase and β-galactosidase under control of the HIV-1
LTR [89] were propagated in DMEM supplemented with
10% fetal bovine serum (FBS), penicillin, streptomycin and
L-glutamine. U87 cells stably expressing CD4 and one of
the chemokine receptors [90] were maintained in DMEM
supplemented with 10% FBS, antibiotics, 1 μg/ml puro-
mycin (Sigma-Aldrich, St. Louis, MO) and 300 μg/ml G418
(Geneticin; Invitrogen, Carlsbad, CA). Rhesus peripheral
blood mononuclear cells (PBMCs) were prepared by Ficoll
gradient centrifugation, stimulated with staphylococcal en-
terotoxin B (SEB, 3 μg/ml ; Sigma-Aldrich), and cultured in
RPMI medium containing 10% FCS, penicillin, strepto-
mycin, L-glutamine and 20U/ml interleukin-2 (Norvatis,
Emeryville, CA). Monocytes were enriched by centrifuga-
tion of human PBMCs through a 40% percoll cushion
followed by plastic adherence, and cultured in RPMI 1640
medium supplemented with 10% FCS and 5% human AB
serum for 5–7 days to allow for differentiation into macro-
phages [91].
SF162P3N molecular clones
Full-length gp160 coding sequences of the R5 SHIVSF162P3N
inoculum were obtained and confirmed as previously
described [41], and subcloned into the corresponding re-
gion of the 3’SHIVSF162 genome [34] using the unique Kpn
I and Xho I sites. Infectious molecular clones were recov-
cells with a ligation product
of the 3’ SHIVSF162 P3N gp160 and the 5’ SIV hemigenomes,
followed by cocultivation with SEB-stimulated rhesus
PBMCs. Stocks of SHIVSF162P3N molecular clones were
propagated and tittered in rhesus PBMCs.
Animal inoculation and clinical assessments
All inoculations were carried out in adult rhesus mon-
keys of Indian origin (Macaca mulatta) housed at the
Tulane National Primate Research Center (TNRPC)
in compliance with the Guide for the Care and Use of
Laboratory Animals. Animals were confirmed to be
serologically and virologically negative for simian type D
retrovirus, and serologically negative for SIV and simian
Materials and methods
293T cells, TZM-bl cells expressing CD4, CCR5 and
ered by cotransfection of 293TT-cell lymphotropic virus prior to infection, and were
screened for the presence of the Mamu-A*01, Mamu-
B*17 and Mamu-B*08 class I alleles previously shown to
be associated with control of pathogenic SIVmac239
replication using standard PCR with allele-specific pri-
mers [92]. Macaques received a single intrarectal (ir)
inoculation with 5 x 103 50% tissue culture infectious
dose (TCID50) of the cell free challenge stocks of
SHIVSF162P3N molecular clones. Whole blood from the
inoculated animals was collected weekly for the first
eight weeks, biweekly for another 16 weeks, and monthly
thereafter. Surgery was performed at peak (2–3 weeks
post-infection, wpi) viremia for collection of tissues from
one external and one internal lymph node, and from in-
ternal organs such as the small intestine, bone marrow,
thymus and spleen. Animals were euthanized at end of
study period by intramuscular administration of telazol
and buprenorphine followed by an overdose of sodium
pentobarbital, and tissues from multiple sites were col-
lected. Euthanasia was considered to be AIDS related
if the animal exhibited peripheral blood CD4+ T-cell
depletion (<200/mm3), greater than 25% loss of body
weight and combinations of the following conditions:
diarrhea unresponsive to treatment, opportunistic infections,
peripheral lymph node atrophy, and abnormal hematology
(e.g., anemia, thrombocytopenia, or leukopenia). Plasma
viremia was quantified by branched DNA analysis (Siemens
Medical Solutions Diagnostic Clinical Lab, Emeryville,
CA) and absolute CD4+ and CD8+ cell counts were moni-
tored by TruCount (BDBiosciences, Palo Alto, CA). The
percentages of CD4+ Tcells in the tissue cells were analyzed
by flow cytometry (FACScalibur) using CD3-fluorescein iso-
thiocyanate (FITC), CD4-phycoerythrin (PE) and CD8- peri-
dinin chlorophyll protein (PerCP) antibodies. Except for
CD3-FITC (BioSource, Camarillo, CA), all antibodies were
obtained from BD Biosciences.
Envelope sequence analysis
For sequence analysis of V3 variants in PBMCs and tis-
sues, proviral DNA was extracted from 3 x 106 cells with
a DNA extraction kit, and the V1 to V5 region of gp120
was amplified from the vDNA using Taq DNA polymer-
ase (Qiagen, Chatsworth, CA) with primers ED5 and
ED12 or ES7 and ES8 as previously described [93]. For
sequence analysis of variants in the plasma, viral RNA
was prepared from 300–500 μl plasma using a commer-
cially available RNA extraction kit (Qiagen) followed by
reverse-transcription (RT) with Superscript III RT (Invi-
trogen, Carlsbad, CA) and random hexamer primers
(Amersham Pharmacia, Piscataway, NJ), with amplifica-
tion of the V1 to V5 region of gp120 from the RT pro-
ducts. The PCR products were cloned with the TOPO
TA cloning kit (Invitrogen) per the manufacturer’s
instructions followed by direct automated sequencing
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were aligned with Clustal X [94], edited manually using
BioEdit V7.0.9 and translated to the amino acid sequence.
Deep sequencing of the inoculating virus stocks was per-
formed using the Solexa Illumina platform by the Gen-
omic Resource Center at the Rockefeller University.
Envelope expression plasmid construction and
pseudotype virus production
The generation of envelope (Env) expression plasmids,
V3 mutants and luciferase-reporter viruses have been
described previously [42]. Briefly, full length gp160 coding
sequence was amplified with primers SH43 (5’-AAGACA
GAATTCATGAGAGTGAAGGGGATCAGGAAG-3’) and
SH44 (5’-AGAGAGGGATCCTTATAGCAAAGCCCTTT
CAAAGCCCT-3’), and subcloned into the pCAGGS vec-
tor. Site-directed mutagenesis was employed to introduce
specific V3 mutations into the backbone of the parental
Envs, and trans-complementation assay was then used to
generate luciferase reporter viruses capable of only a single
round of replication. The pseudovirions were quantified for
p24gag content (Beckman Coulter, Fullerton, CA).
Determination of coreceptor usage
For assessment of coreceptor usage, 7 x 103 U87.CD4.
CCR5 or U87.CD4.CXCR4 cells were seeded in 96-well
plates 24 hours before use and infected, in triplicate, with
5 ng p24gag equivalent of the indicated pseudovirions fol-
lowed by incubation for 72 h at 37°C. At the end of the in-
cubation period, the cells were harvested, lysed and
processed for activity according to the manufacturer’s
instructions (Luciferase Assay System; Promega, Madison,
WI). Entry, as quantified by relative light unit (RLU), was
measured with an MLX microtiter plate luminometer
(Dynex Technologies, Inc., Chantilly, VA). For assessment
of coreceptor utilization in rhPBMCs, blocking with
CCR5 (TAK779) and CXCR4 (AMD3100) inhibitors was
performed. Briefly, 5 x 106 SEB-stimulated cells were
infected with 200 TCID50 of the indicated SHIV in the
presence or absence of 1 μM of the chemokine receptor
inhibitors. After incubation for 2 hours at 37°C, cells were
washed and cultured in 1.5 ml interleukin-2 and appropri-
ate inhibitor-supplemented RPMI medium in each well of
a 24-well plate. Culture supernatants were collected over
time, and p27gag antigen content was quantified according
to the Manufacturer’s instructions (ZeptoMetrix, Buffalo,
NY). Percentage blocking at 6 days post-infection was
determined by calculating the amount of p27gag antigen
production in the presence relative to that in the absence
of the inhibitor.
Detection of antiviral humoral response
The titers of SHIV-specific antibodies were measured by
enzyme-linked immunosorbent assay (ELISA) accordingto the manufacturer’s instructions (GS HIV-1/HIV-2
PLUS O EIA; Bio-Rad, Redmond, WA). Endpoint titers
were determined as the reciprocal of the highest serum
dilution that resulted in an optical density reading
greater than the average values obtained with negative
human sera plus three standard deviations. Autologous
virus neutralization was assessed using TZM-bl cells in
96-well plates. Briefly, equal volumes (50 μl) of the in-
oculating virus were incubated with 4-fold serial dilu-
tions of heat-inactivated sera from infected macaques
for 1 hour at 37°C and then added to cells, in duplicate
wells, for an additional 2 hours at 37°C. 100 μl of
medium was then added to each well and the virus-
antibody (Ab) cultures maintained for 72 hours. Control
cultures received virus in the absence of SHIV sera. At
the end of the culture period, the cells were lysed and
processed for β-galactosidase activity. A neutralization
curve was generated by plotting the percentage of
neutralization vs serum dilution, and 50% inhibitory di-
lution (ID50) titer was determined using the Prism 4
software (GraphPad, San Diego, CA). Neutralization
titers are expressed as the reciprocal of the plasma dilu-
tion that inhibited virus infection by 50% (ID50). The
lowest serum dilution used in the assay was 1:20.
Immunophenotyping of SHIV-infected cells
Identification of SHIV-infected cells was accomplished
with double-label immunohistochemistry performed as
previously described with modifications [95,96]. Briefly,
lymph node sections were deparaffinized in xylene and
rehydrated through graded ethanol to tris-buffered saline
(TBS) plus tween 20. Endogenous peroxidase activity
was blocked by incubation in 3% H2O2 in PBS. Antigen
retrieval was accomplished by microwave heating sec-
tions at 95°C for 20 minutes in citrate buffer (Vector La-
boratories, Burlingame, CA), followed by 20 minute
cooling, and Dako protein block (Carpinteria, CA) for
10 minutes. The blocked sections were incubated with
SIVnef antibody (clone KK75, IgG1; 1:200) overnight at
4°C then reacted with biotinylated secondary antibody
(HAM-b, Dako, 1:200) for 30 minutes. Sections were
detected using standard avidin-biotin peroxidase com-
plex technique (ABC Elite, Vector Laboratories) and
DAB chromagen (Dako). Sections were blocked again
for 10 minutes with protein block (Dako) and incubated
with Iba-1 antibody (Wako Chemicals, Richmond, VA,
rabbit polyclonal, 019–19741, 1:1000) for macrophages
for 30 minutes at room temperature followed by biotiny-
lated secondary antibody (GAR-b, Dako, 1:200) for
30 minutes. Sections were detected using standard
avidin-biotin alkaline phosphatase complex technique
(Vectastain ABC-AP, Vector Laboratories) and Perman-
ent Red (Dako). Slides were counterstained with Mayer’s
hematoxylin, rinsed in tap water, coated with Clear
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dried overnight, then coverslipped.
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